Drug intelligence / Profile preview

TBE025

Development stage: Phase 1
Lead developer: Centre Hospitalier Universitaire Vaudois
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TBE025 is a recombinant, fully human monoclonal antibody (mAb) developed for the potential treatment or prevention of tick-borne encephalitis (TBE). It is designed to target and neutralize the Tick-borne Encephalitis Virus (TBEV), a member of the Flaviviridae family that causes significant neurological disease. By binding to the virus, TBE025 aims to prevent viral entry into host cells and facilitate the clearance of the pathogen. The drug is currently being evaluated in Phase I clinical trials, led by Giuseppe Pantaleo, to investigate its safety, tolerability, and pharmacokinetic profile in healthy adult volunteers following intravenous administration.

Other names: Human monoclonal antibody TBE025

Targets

E (Tick-borne encephalitis virus envelope protein)

Beyond the preview

Go deeper on TBE025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TBE025.

Explore the full profile